Roivant Sciences/$ROIV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Ticker
- $ROIV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 721
- Headquarters
- London, United Kingdom
- Website
- roivant.com
Roivant Sciences Metrics
BasicAdvanced
$28B
-
-$0.49
1.10
-
Price and volume
Market cap
$28B
Beta
1.1
52-week high
$42.50
52-week low
$19.62
Average daily volume
6.5M
Financial strength
Current ratio
16.721
Quick ratio
13.624
Long term debt to equity
0.019
Total debt to equity
0.022
Profitability
EBITDA (TTM)
-1,343.527
Gross margin (TTM)
-9,610.89%
Net profit margin (TTM)
-3,534.96%
Operating margin (TTM)
-17,875.42%
Effective tax rate (TTM)
-43.03%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-16.28%
Return on equity (TTM)
-8.52%
Valuation
Price to revenue (TTM)
3,573.231
Price to book
6.53
Price to tangible book (TTM)
6.53
Price to free cash flow (TTM)
-32.779
Free cash flow yield (TTM)
-3.05%
Free cash flow per share (TTM)
-1.166
Growth
Revenue change (TTM)
-67.58%
Earnings per share change (TTM)
-29.49%
3-year revenue growth (CAGR)
-50.32%
3-year earnings per share growth (CAGR)
-28.56%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Analyst projections of the future price of Roivant Sciences stock.
Bulls say / Bears say
Brepocitinib delivered strong Phase 3 results in non-infectious uveitis: both CLARITY trials met their primary and key secondary endpoints, and 62% of patients achieved steroid-free disease control at week 48 versus 20% on placebo. Priovant plans to file for this use in the first half of 2027. (Roivant Sciences)
Roivant reported $3.9bn in cash, equivalents, restricted cash and marketable securities at June 30, before receiving a further $950m from Moderna in July. This gives it substantial funding to advance its pipeline and support its commercial launch. (Roivant Sciences)
Mosliciguat produced positive Phase 2 results in pulmonary hypertension linked to interstitial lung disease, and Roivant has started a Phase 3 study. This gives the company another late-stage opportunity beyond brepocitinib. (Roivant Sciences)
IMVT-1402 failed to meet the main endpoint in a proof-of-concept study for cutaneous lupus, and Immunovant plans to stop development for that condition. The result highlights the risk that other pipeline programmes may also disappoint. (Seeking Alpha)
The new LISRAYA launch is still early, with management describing a gradual rollout and saying it is too soon to judge uptake. Roivant previously struggled to build sales of VTAMA, showing that clinical success does not guarantee strong commercial execution. (BioSpace, Investing.com)
Revenue was just $1.44m in the quarter, while operating expenses rose to $368m and the net loss widened to $291m year on year. Roivant therefore remains dependent on its cash reserves as it funds costly trials and launches. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Roivant Sciences News
AllArticlesVideos
Funds containing Roivant Sciences
Fund name | Fund size | $ROIV weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.67% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.67% |
iShares Healthcare Innovation£DRDR | $1.3B | 1.45% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.45% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.45% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.